The Avandia (rosiglitazone) debate will heat up again now that FDA will loosen its restrictions

The Avandia (rosiglitazone) debate will heat up again now that FDA will loosen its restrictions.

This decision is based on a reanalysis of the RECORD trial that suggests Avandia DOES NOT increase cardiovascular risk.

But experts warn that reanalyzing a flawed study doesn't make it valid...and other studies DO suggest Avandia increases CV risk.